SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

TCS recognized as leader for Worldwide Life Science R&D DCT Technology Solutions

27 Oct 2022 Evaluate

Tata Consultancy Services (TCS) has been named a leader in the IDC MarketScape for Worldwide Life Science R&D Decentralized Clinical Trial (DCT) Technology Solutions. According to the report, TCS' differentiators include the breadth of DCT capabilities that it offers, the ease of implementation of its solutions, and its competitive pricing. Its value proposition for DCTs is its end-to-end integrated platform and its ecosystem play.

TCS ADD Connected Clinical Trials is a comprehensive suite of AI/ML-based platforms for decentralized trials. It provides a unified interface for patients and sites, facilitates collaboration with stakeholders such as regulators, sites, and health authorities, and enables patient-centric trials. The platform connects patients, sites, and sponsors through a variety of innovative sensors, smart medication packages, and mobile devices, to enhance trial outcomes. It caters to operations across the clinical studies lifecycle including e-consent, smart questionnaire (eCOA, diaries and surveys), an industry first supply management platform that brings together kit tracking, digital labels, and unit/dose tracking (medication adherence), and telemedicine.

The platform is comprehensive, interoperable and supports eco-system interplay, has multilingual capabilities, as well as the ability to be hosted on multi-cloud and multi-region. In addition, TCS ADD Connected Clinical Trials supports automated data collection, enables remote monitoring and oversight suitable for high frequency and a high volume of data.

TCS is an IT services, consulting and business solutions organization that has been partnering with many of the world’s largest businesses in their transformation journeys for over 50 years.

TCS Share Price

2069.05 21.30 (1.04%)
10-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
TCS 2069.05
Infosys 1068.05
HCL Technologies 1162.65
Wipro 175.35
Tech Mahindra 1455.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: